Autumn inflection point: approvals, AI, and capital are putting life sciences into overdrive. As summer turns to fall, the sector is accelerating, not slowing—driven by a cluster of FDA approvals in high‑unmet‑need diseases, breakthrough gene therapies, new guidance for AI‑enabled and microbiome-based technologies, and rising deal and funding activity. For biopharma leaders and investors, this late‑summer surge signals a pivotal moment to engage, partner, and deploy capital a

Your first five hires will decide whether your “platform biotech” ever becomes more than a pitch deck. In the first 18 months you’re not building an org chart, you’re building an engine: one person who truly owns the platform, one who runs everything that isn’t science, one who turns data into a scalable system, an early regulatory voice to stop you tripping over yourself later, and a business partner who keeps capital and deals flowing.

Thoughts from the beach - Ageing, learning and seniorlytics! Last weekend, I spent a day at the beach with family and friends aged 6 to 70. The younger ones threw themselves into the sea and into sandcastle building—fearless, curious, and quick to learn from mistakes. The older adults contributed stories and thoughtful advice, grounding our fun in lived experience. Children are called “sponges” for good reason: their brains form up to a million new connections every second (H